AHR antagonist 2

发表于2024年3月16日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

AHR antagonist 2 纯度: 99.48%

AHR antagonist 2 是一种有效的芳香烃受体 (AHR) 拮抗剂，对人和小鼠的 IC₅₀ 值分别为 0.885，2.03 nM，详情请参见专利 WO2019101641A1，example 1。

AHR antagonist 2 Chemical Structure

CAS No. : 2338747-54-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥2750	In-stock
5 mg	￥2500	In-stock
10 mg	￥4000	In-stock
50 mg	￥9800	In-stock
100 mg	￥15000	In-stock
250 mg	￥22000	In-stock
500 mg		询价
1 g		询价

* Please select Quantity before adding items.

AHR antagonist 2 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Transcription Factor Targeted Library

生物活性

AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC₅₀s of 0.885 and 2.03 nM for human and mouse AhR^[1].

分子量

418.37

Formula

C₂₀H₁₇F₃N₄O₃

CAS 号

2338747-54-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (597.56 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3902 mL	11.9511 mL	23.9023 mL
5 mM	0.4780 mL	2.3902 mL	4.7805 mL
10 mM	0.2390 mL	1.1951 mL	2.3902 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Julien LEFRANC, et al. 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists. WO2019101641A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RAGE antagonist peptide TFA

发表于2024年3月11日由上海金畔生物科技有限公司

RAGE antagonist peptide TFA 纯度: 99.04%

RAGE antagonist peptide TFA 是一种晚期糖基化终产物 (RAGE) 拮抗剂。RAGE antagonist peptide TFA 可阻断 RAGE 和几个重要配体 HMGB-1，S100P，S100A4 的结合。RAGE antagonist peptide TFA 具有抗肿瘤和抗炎活性。

RAGE antagonist peptide TFA Chemical Structure

规格	价格	是否有货
1 mg	￥890	In-stock
5 mg	￥2700	In-stock
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

RAGE antagonist peptide TFA 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Neuronal Signaling Compound Library
Anti-Cancer Compound Library
Anti-Alzheimer’s Disease Compound Library
Neurodegenerative Disease-related Compound Library
Peptide Library

生物活性

RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities^[1]^[2].

体外研究
(In Vitro)

RAGE antagonist peptide TFA (RAP) reduces the ability of the ligands to stimulate RAGE activation of NFκB in cancer cells in vitro^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

RAGE antagonist peptide TFA (RAP, 100 µg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo^[1].
RAGE antagonist peptide TFA (RAP) reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth^[1].
In mice bearing asthma, RAGE antagonist peptide TFA (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide TFA also reduces total, cytoplasmic and nuclear levels of β-catenin, enhances β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice^[1].
Dosage:	100 µg
Administration:	Intratumoral delivery (or intraperitoneally).
Result:	Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection.

分子量

1386.58

Formula

C₅₉H₁₀₂F₃N₁₃O₁₉S

Sequence Shortening

Ac-ELKVLMEKEL-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 25 mg/mL (18.03 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7212 mL	3.6060 mL	7.2120 mL
5 mM	0.1442 mL	0.7212 mL	1.4424 mL
10 mM	0.0721 mL	0.3606 mL	0.7212 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献

[1]. Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.

[2]. Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

A2A receptor antagonist 1(Synonyms: CPI-444 analog)

发表于2024年3月10日由上海金畔生物科技有限公司

A2A receptor antagonist 1 (Synonyms: CPI-444 analog) 纯度: 99.96%

A2A receptor antagonist 1 (CPI-444 analog) 是 adenosine A_2A receptor 和 A₁ receptor 的拮抗剂，K_i 值分别为 4 和 264 nM 。

A2A receptor antagonist 1 Chemical Structure

CAS No. : 443103-97-7

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥680	In-stock
1 mg	￥700	In-stock
5 mg	￥1000	In-stock
10 mg	￥1600	In-stock
50 mg	￥6300	In-stock
100 mg	￥11000	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

A2A receptor antagonist 1 相关产品

•相关化合物库:

Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Anti-Cancer Compound Library
Small Molecule Immuno-Oncology Compound Library
Neurotransmitter Receptor Compound Library
Anti-Parkinson’s Disease Compound Library
Neurodegenerative Disease-related Compound Library

生物活性

A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A_2A receptor and A₁ receptor with K_i values of 4 and 264 nM, respectively^[1].

IC₅₀ & Target

Ki: 4 nM (adenosine A_2A receptor), 264 nM (A₁ receptor)^[1]

体外研究
(In Vitro)

A2A receptor antagonist 1 (CPI-444 analog) is a potent adenosine A_2A receptor antagonist, selective over the A1 receptor and demonstrates its binding activity with K_i values of 4 and 264 nM, respectively^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

309.30

Formula

C₁₆H₁₂FN₅O

CAS 号

443103-97-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 25 mg/mL (80.83 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2331 mL	16.1655 mL	32.3311 mL
5 mM	0.6466 mL	3.2331 mL	6.4662 mL
10 mM	0.3233 mL	1.6166 mL	3.2331 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.08 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.08 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.08 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Gillespie RJ, et al. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

LPA2 antagonist 2

发表于2024年3月2日由上海金畔生物科技有限公司

LPA2 antagonist 2 纯度: 95.03%

LPA2 antagonist 2 是一种选择性 LPA₂ 拮抗剂，IC₅₀ 为 28.3 nM，K_i 为 21.1 nM，比 LPA₃ (IC₅₀ 为 13.85 μM) 选择性高 480 倍以上。

LPA2 antagonist 2 Chemical Structure

CAS No. : 36840-10-5

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2930	In-stock
1 mg	￥1200	In-stock
5 mg	￥3500	In-stock
10 mg	￥5500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

LPA2 antagonist 2 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Covalent Screening Library

生物活性

LPA2 antagonist 2 (H2L 5226501) is a selective LPA₂ antagonist with an IC₅₀ of 28.3 nM and a K_i of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA₃ (IC₅₀ of 13.85 μM)^[1].

IC₅₀ & Target

IC50: 28.3 nM (LPA₂); 13.85 μM (LPA₃)^[1]

体外研究
(In Vitro)

Lysophosphatidic acid (LPA) is a phospholipid mediator that elicits a host of biological effects including cell proliferation, survival, motility and differentiation. LPA has been shown to regulate cancer cell invasion, metastasis, and resistance to both chemotherapeutics and radiation. LPA2 antagonist 2 (H2L 5226501) inhibits LPA₁ with an Imax of 59.0% at 30 µM^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

380.35

Formula

C₂₀H₁₆N₂O₆

CAS 号

36840-10-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 83.33 mg/mL (219.09 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6292 mL	13.1458 mL	26.2916 mL
5 mM	0.5258 mL	2.6292 mL	5.2583 mL
10 mM	0.2629 mL	1.3146 mL	2.6292 mL

参考文献

[1]. Fells JI, et al. Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg Med Chem. 2008 Jun 1;16(11):6207-17.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CXCR7 antagonist-1

发表于2024年2月22日由上海金畔生物科技有限公司

CXCR7 antagonist-1

CXCR7 antagonist-1 是SDF-1 趋化因子 (CXCL12) 或 I-TAC (CXCL11) 与趋化因子受体 CXCR 结合的抑制剂。CXCR7 antagonist-1 可防止肿瘤细胞增殖、肿瘤形成、炎症性疾病和许多其他疾病 (信息来自专利WO2014085490A1，化合物1.128)。

CXCR7 antagonist-1 Chemical Structure

CAS No. : 1613021-99-0

规格	价格	是否有货
5 mg	￥5800	询问价格 & 货期
10 mg	￥9800	询问价格 & 货期

* Please select Quantity before adding items.

生物活性

CXCR7 antagonist-1 is an inhibitor of the binding of the SDF-1 chemokine (CXCL12 chemokine) or I-TAC (CXCL11) to the chemokine receptor CXCR. CXCR7 antagonist-1 prevents tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128)^[1].

IC₅₀ & Target

CXCR7

分子量

390.41

Formula

C₂₁H₁₉FN₆O

CAS 号

1613021-99-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Junfa Fan, et al. Cxcr7 antagonists. Patent WO2014085490A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Androgen receptor antagonist 1

发表于2024年2月16日由上海金畔生物科技有限公司

Androgen receptor antagonist 1 纯度: 99.39%

Androgen receptor antagonist 1 是一种口服有效的完整雄激素受体 (AR) 拮抗剂，IC₅₀ 为 59 nM。Androgen receptor antagonist 1 可用于合成 PROTAC AR 降解剂，1 μM 和 10 μM PROTAC AR 降解剂作用于 LNCaP 细胞，分别导致 24% 和 47% AR 蛋白降解。

Androgen receptor antagonist 1 Chemical Structure

CAS No. : 1338812-36-4

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥4950	In-stock
5 mg	￥4500	In-stock
10 mg	￥8000	In-stock
25 mg	￥15500	In-stock
50 mg	￥23500	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

Androgen receptor antagonist 1 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Anti-Cancer Compound Library
Transcription Factor Targeted Library

生物活性

Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC₅₀ of 59 nM^[1]. Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively^[2].

IC₅₀ & Target

IC50: 59 nM (androgen receptor)^[1]

体外研究
(In Vitro)

Androgen receptor antagonist 1 (Compound 26; 1 nM-100 μM) shows significant cell growth inhibition effects for LNCaP and LNAR cells but not DU145 cells^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Prostate cancer (CaP) cells (LNCAP, LNAR, and DU145)
Concentration:	1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
Incubation Time:	7 days
Result:	Antiproliferative effects of in LNCAP and LNAR cells.

体内研究
(In Vivo)

Androgen receptor antagonist 1 (Compound 26; 100 mg/kg once a day for 5 weeks) demonstrates excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice with LNCaP xenograft model of CRPC^[1]
Dosage:	100 mg/kg
Administration:	Orally once a day for 5 weeks
Result:	Demonstrated outstanding efficacy in inhibiting tumor growth. At the given doses (100 mg/kg once a day) nearly completely suppressed tumor growth (by 90 %) and the PSA levels (78%) after 5 weeks, with no detectable body weight loss for the period of time when animals were treated.

分子量

416.90

Formula

C₂₁H₂₅ClN₄O₃

CAS 号

1338812-36-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (239.87 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3987 mL	11.9933 mL	23.9866 mL
5 mM	0.4797 mL	2.3987 mL	4.7973 mL
10 mM	0.2399 mL	1.1993 mL	2.3987 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.00 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Guo C, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10;54(21):7693-704.

[2]. Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GPR4 antagonist 1

发表于2024年2月9日由上海金畔生物科技有限公司

GPR4 antagonist 1

GPR4 antagonist 1 是 GPR4 的拮抗剂，其 IC₅₀ 值为 189 nM。

GPR4 antagonist 1 Chemical Structure

CAS No. : 1197879-16-5

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	GPR4 antagonist 1 is a GPR4 antagonist, with an IC₅₀ of 189 nM.
IC₅₀ & Target	IC50: 189 nM (GPR4)^[1].
分子量	431.62
Formula	C₂₇H₃₇N₅
CAS 号	1197879-16-5
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. ARYL SULFONOHYDRAZIDES. US 20090291942 A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制IFN-gamma Antagonist 编码 [158040-83-6]

发表于2024年2月6日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	IFN-gamma Antagonist
编码	[158040-83-6]
别名	IFN-gamma Antagonist
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	AYC(Acm)RDGKIGPPKLDIRKEEKQI
序列（三字母缩写）	H-Ala-Tyr-Cys(Acm)-Arg-Asp-Gly-Lys-Ile-Gly-Pro-Pro-Lys-Leu-Asp-Ile-Arg-Lys-Glu-Glu-Lys-Gln-Ile-OH (trifluoroacetate salt)
基本描述	Useful FRET substrate for a continuous fluorescence-based assay of the malaria aspartyl protease (plasmepsin). The peptide sequence ERNleFLSFP is derived from the cleavage site present in hemoglobin, with Nle as a substitution for Met to avoid potential oxidation related problems.
溶解度
分子量	2629.08
化学式	C115H194N34O34S1
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference	G.F.Seelig et al., J. Biol. Chem., 270, 9241 (1995)
C端
N端
化学桥

多肽定制IFN-γ Antagonist 编码

发表于2024年2月6日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	IFN-γ Antagonist
编码
别名	IFN-γ Antagonist
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	AY-Cys(Acm)-RDGKIGPPKLDIRKEEKQI-OH
序列（三字母缩写）	Ala-Tyr-Cys(Acm)-Arg-Asp-Gly-Lys-Ile-Gly-Pro-Pro-Lys-Leu-Asp-Ile-Arg-Lys-Glu-Glu-Lys-Gln-Ile
基本描述
溶解度
分子量	0
化学式
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

Antagonist G TFA

发表于2024年1月26日由上海金畔生物科技有限公司

Antagonist G TFA

Antagonist G TFA 是有效的后叶加压素 (vasopressin) 的拮抗剂。Antagonist G 也是弱的GRP 和缓激肽的弱拮抗剂。Antagonist G 可诱导 AG-1 的转录，是癌细胞对化疗增敏。

Antagonist G TFA Chemical Structure

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Antagonist G TFA 的其他形式现货产品:

Antagonist G

生物活性

Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy^[1]^[2].

体外研究
(In Vitro)

Antagonist G (0-100 μM) induces apoptosis is redox-sensitive and caspase-dependently in SCLC cells^[2].
Antagonist G activates JNK1 in SCLC cells^[2].
Antagonist G is not intrinsically a free radical oxygen donor but stimulates free radical generation specifically within SCLC cells (6.2-fold) and increases the activity of the redox-sensitive transcription factor AP-1 by 61%^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	SCLC cell lines NCI-H69, NCI-H510 and CHO-K1 cells.
Concentration:	0-100 μM.
Incubation Time:	24 h.
Result:	Inhibited cell growh.

分子量

1065.21

Formula

C₅₁H₆₇F₃N₁₂O₈S

Sequence Shortening

RW-{Me-Phe}-WLM-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. P J Woll, et al. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res. 1990 Jul 1;50(13):3968-73.

[2]. A C MacKinnon, et al. [Arg6, D-Trp7,9, NmePhe8]-substance P (6–11) (antagonist G) inducesP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer. 2000 Oct; 83(7): 941–948.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Antagonist G TFA

发表于2024年1月26日由上海金畔生物科技有限公司

Antagonist G TFA

Antagonist G TFA Chemical Structure

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Antagonist G TFA 的其他形式现货产品:

Antagonist G

生物活性

体外研究
(In Vitro)

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	SCLC cell lines NCI-H69, NCI-H510 and CHO-K1 cells.
Concentration:	0-100 μM.
Incubation Time:	24 h.
Result:	Inhibited cell growh.

分子量

1065.21

Formula

C₅₁H₆₇F₃N₁₂O₈S

Sequence Shortening

RW-{Me-Phe}-WLM-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. P J Woll, et al. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res. 1990 Jul 1;50(13):3968-73.

[2]. A C MacKinnon, et al. [Arg6, D-Trp7,9, NmePhe8]-substance P (6–11) (antagonist G) inducesP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer. 2000 Oct; 83(7): 941–948.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Antagonist G TFA

发表于2024年1月26日由上海金畔生物科技有限公司

Antagonist G TFA

Antagonist G TFA Chemical Structure

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Antagonist G TFA 的其他形式现货产品:

Antagonist G

生物活性

体外研究
(In Vitro)

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	SCLC cell lines NCI-H69, NCI-H510 and CHO-K1 cells.
Concentration:	0-100 μM.
Incubation Time:	24 h.
Result:	Inhibited cell growh.

分子量

1065.21

Formula

C₅₁H₆₇F₃N₁₂O₈S

Sequence Shortening

RW-{Me-Phe}-WLM-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. P J Woll, et al. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res. 1990 Jul 1;50(13):3968-73.

[2]. A C MacKinnon, et al. [Arg6, D-Trp7,9, NmePhe8]-substance P (6–11) (antagonist G) inducesP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer. 2000 Oct; 83(7): 941–948.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RAGE antagonist peptide

发表于2024年1月19日由上海金畔生物科技有限公司

RAGE antagonist peptide

RAGE antagonist peptide 是一种晚期糖基化终产物 (RAGE) 拮抗剂。RAGE antagonist peptide (RAP) 可阻断 RAGE 和几个重要配体 HMGB-1、S100P、S100A4 的结合。RAGE antagonist peptide (RAP) 具有抗肿瘤和抗炎活性。

RAGE antagonist peptide Chemical Structure

CAS No. : 1092460-91-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

RAGE antagonist peptide 的其他形式现货产品:

RAGE antagonist peptide TFA

生物活性

RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities^[1]^[2].

体外研究
(In Vitro)

RAGE antagonist peptide (RAP) reduces the ability of the ligands to stimulate RAGE activation of NFκB in cancer cells in vitro^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

RAGE antagonist peptide (RAP, 100 µg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo^[1].
RAGE antagonist peptide (RAP) reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth^[1].
In mice bearing asthma, RAGE antagonist peptide (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice^[1].
Dosage:	100 µg.
Administration:	Intratumoral delivery (or intraperitoneally).
Result:	Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection.

分子量

1272.56

Formula

C₅₇H₁₀₁N₁₃O₁₇S

CAS 号

1092460-91-7

Sequence Shortening

Ac-ELKVLMEKEL-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.

[2]. Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RAGE antagonist peptide

发表于2024年1月19日由上海金畔生物科技有限公司

RAGE antagonist peptide

RAGE antagonist peptide Chemical Structure

CAS No. : 1092460-91-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

RAGE antagonist peptide 的其他形式现货产品:

RAGE antagonist peptide TFA

生物活性

体外研究
(In Vitro)

RAGE antagonist peptide (RAP) reduces the ability of the ligands to stimulate RAGE activation of NFκB in cancer cells in vitro^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice^[1].
Dosage:	100 µg.
Administration:	Intratumoral delivery (or intraperitoneally).
Result:	Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection.

分子量

1272.56

Formula

C₅₇H₁₀₁N₁₃O₁₇S

CAS 号

1092460-91-7

Sequence Shortening

Ac-ELKVLMEKEL-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.

[2]. Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RAGE antagonist peptide

发表于2024年1月19日由上海金畔生物科技有限公司

RAGE antagonist peptide

RAGE antagonist peptide Chemical Structure

CAS No. : 1092460-91-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

RAGE antagonist peptide 的其他形式现货产品:

RAGE antagonist peptide TFA

生物活性

体外研究
(In Vitro)

RAGE antagonist peptide (RAP) reduces the ability of the ligands to stimulate RAGE activation of NFκB in cancer cells in vitro^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice^[1].
Dosage:	100 µg.
Administration:	Intratumoral delivery (or intraperitoneally).
Result:	Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection.

分子量

1272.56

Formula

C₅₇H₁₀₁N₁₃O₁₇S

CAS 号

1092460-91-7

Sequence Shortening

Ac-ELKVLMEKEL-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.

[2]. Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AHR antagonist 4

发表于2024年1月18日由上海金畔生物科技有限公司

AHR antagonist 4

AHR antagonist 4 是一种有效的芳基烃受体 (AHR) 拮抗剂，其 IC₅₀ 为 82.2 nM，详细信息请参考专利文献 WO2018146010A1 中的化合物 293。

AHR antagonist 4 Chemical Structure

CAS No. : 2242465-58-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	AHR antagonist 4 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and a potent aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 293, has an IC₅₀ of 82.2 nM. AHR antagonist 4 has anti-cancer effects^[1].
IC₅₀ & Target	IC50: 82.2 nM (Aryl hydrocarbon receptor (AHR))^[1]
分子量	488.34
Formula	C₂₀H₁₄F₆N₄O₄
CAS 号	2242465-58-1
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AHR antagonist 4

发表于2024年1月18日由上海金畔生物科技有限公司

AHR antagonist 4

AHR antagonist 4 是一种有效的芳基烃受体 (AHR) 拮抗剂，其 IC₅₀ 为 82.2 nM，详细信息请参考专利文献 WO2018146010A1 中的化合物 293。

AHR antagonist 4 Chemical Structure

CAS No. : 2242465-58-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	AHR antagonist 4 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and a potent aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 293, has an IC₅₀ of 82.2 nM. AHR antagonist 4 has anti-cancer effects^[1].
IC₅₀ & Target	IC50: 82.2 nM (Aryl hydrocarbon receptor (AHR))^[1]
分子量	488.34
Formula	C₂₀H₁₄F₆N₄O₄
CAS 号	2242465-58-1
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AHR antagonist 4

发表于2024年1月18日由上海金畔生物科技有限公司

AHR antagonist 4

AHR antagonist 4 是一种有效的芳基烃受体 (AHR) 拮抗剂，其 IC₅₀ 为 82.2 nM，详细信息请参考专利文献 WO2018146010A1 中的化合物 293。

AHR antagonist 4 Chemical Structure

CAS No. : 2242465-58-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	AHR antagonist 4 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and a potent aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 293, has an IC₅₀ of 82.2 nM. AHR antagonist 4 has anti-cancer effects^[1].
IC₅₀ & Target	IC50: 82.2 nM (Aryl hydrocarbon receptor (AHR))^[1]
分子量	488.34
Formula	C₂₀H₁₄F₆N₄O₄
CAS 号	2242465-58-1
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EP4 receptor antagonist 3

发表于2024年1月2日由上海金畔生物科技有限公司

EP4 receptor antagonist 3

EP4 receptor antagonist 3 是一种有效的 EP4 receptor 拮抗剂，例 3，源于专利产品 WO2010019796 A1。EP4 receptor antagonist 3 可用于 EP4 受体介导的疾病的研究，如急慢性疼痛、骨关节炎、类风湿关节炎和癌症。

EP4 receptor antagonist 3 Chemical Structure

CAS No. : 1207954-34-4

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

EP4 receptor antagonist 3 is a potent EP4 receptor antagonist, example 3,extracted from patent WO2010019796 A1. EP4 receptor antagonist 3 can be used for the reseacrh of EP4 receptor-mediated diseases, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer^[1].

IC₅₀ & Target^[1]

EP4

分子量

498.52

Formula

C₂₆H₂₁F₃N₂O₃S

CAS 号

1207954-34-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Wei W. Yuan, et al. Heterocyclic amide derivatives as ep4 receptor antagonists. Patent WO2010019796A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EP4 receptor antagonist 3

发表于2024年1月2日由上海金畔生物科技有限公司

EP4 receptor antagonist 3

EP4 receptor antagonist 3 Chemical Structure

CAS No. : 1207954-34-4

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

IC₅₀ & Target^[1]

EP4

分子量

498.52

Formula

C₂₆H₂₁F₃N₂O₃S

CAS 号

1207954-34-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Wei W. Yuan, et al. Heterocyclic amide derivatives as ep4 receptor antagonists. Patent WO2010019796A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

whatman (沃特曼)

英国沃特曼 Millipore PALL中国代理商金畔官网

标签归档：antagonist

AHR antagonist 2

AHR antagonist 2 相关产品

•相关化合物库:

RAGE antagonist peptide TFA

RAGE antagonist peptide TFA 相关产品

•相关化合物库:

A2A receptor antagonist 1(Synonyms: CPI-444 analog)

A2A receptor antagonist 1 相关产品

•相关化合物库:

LPA2 antagonist 2

LPA2 antagonist 2 相关产品

•相关化合物库:

CXCR7 antagonist-1

Androgen receptor antagonist 1

Androgen receptor antagonist 1 相关产品

•相关化合物库:

GPR4 antagonist 1

多肽定制IFN-gamma Antagonist 编码 [158040-83-6]

多肽定制IFN-γ Antagonist 编码

Antagonist G TFA

Antagonist G TFA

Antagonist G TFA

RAGE antagonist peptide

RAGE antagonist peptide

RAGE antagonist peptide

AHR antagonist 4

AHR antagonist 4

AHR antagonist 4

EP4 receptor antagonist 3

EP4 receptor antagonist 3